Vetr lowered shares of Cara Therapeutics, Inc. (NASDAQ:CARA) from a buy rating to a hold rating in a research note released on Tuesday, June 27th. Vetr currently has $25.38 price objective on the biopharmaceutical company’s stock.

CARA has been the topic of several other research reports. Stifel Nicolaus restated a buy rating and issued a $20.00 price target (down previously from $24.00) on shares of Cara Therapeutics in a research note on Friday, June 23rd. HC Wainwright restated a buy rating and issued a $30.00 price target on shares of Cara Therapeutics in a research note on Monday, April 24th. Janney Montgomery Scott set a $20.00 price target on shares of Cara Therapeutics and gave the company a buy rating in a research note on Saturday, March 11th. Raymond James Financial, Inc. restated a market perform rating and issued a $30.00 price target on shares of Cara Therapeutics in a research note on Friday, April 28th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $23.00 price target on shares of Cara Therapeutics in a research note on Friday, March 3rd. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $25.68.

Shares of Cara Therapeutics (NASDAQ CARA) traded up 10.11% during midday trading on Tuesday, reaching $15.36. The company’s stock had a trading volume of 6,603,859 shares. Cara Therapeutics has a one year low of $4.75 and a one year high of $28.50. The stock’s 50-day moving average is $18.44 and its 200-day moving average is $15.55. The company’s market capitalization is $499.31 million.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $0.11 million. The firm’s revenue for the quarter was up 12900.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.39) EPS. On average, equities analysts expect that Cara Therapeutics will post ($2.44) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/16/cara-therapeutics-inc-cara-downgraded-by-vetr-inc-to-hold-updated-updated.html.

In related news, Director Dean Slagel sold 250,000 shares of the company’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $25.87, for a total value of $6,467,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company’s stock.

Several large investors have recently modified their holdings of CARA. FMR LLC bought a new stake in Cara Therapeutics during the fourth quarter worth about $845,000. Private Advisor Group LLC increased its stake in Cara Therapeutics by 120.5% in the first quarter. Private Advisor Group LLC now owns 23,737 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 12,970 shares during the last quarter. Creative Planning increased its stake in Cara Therapeutics by 9.3% in the first quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 1,215 shares during the last quarter. State Street Corp increased its stake in Cara Therapeutics by 7.1% in the fourth quarter. State Street Corp now owns 348,531 shares of the biopharmaceutical company’s stock worth $3,244,000 after buying an additional 23,222 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Cara Therapeutics by 37.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 229,626 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 62,518 shares during the last quarter. Institutional investors and hedge funds own 52.91% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.